500 reports of this reaction
2.1% of all HUMAN INSULIN reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for HUMAN INSULIN, manufactured by Novo Nordisk. There are 500 FDA adverse event reports linking HUMAN INSULIN to DYSPNOEA. This represents approximately 2.1% of all 24,125 adverse event reports for this drug.
Patients taking HUMAN INSULIN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for HUMAN INSULIN, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for HUMAN INSULIN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 500 FDA reports for HUMAN INSULIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.1% of all adverse event reports for HUMAN INSULIN, making it a notable side effect.
If you experience dyspnoea while taking HUMAN INSULIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.